Professor Hashim Ahmed

Consultant Urological Surgeon

QualificationsFRCS(Urol), PhD, MA, BM, BCh

Languages spoken:English, Bengali

GMC number:


Main NHS base:

  • Chair of Urology and Consultant Urological Surgeon, Imperial College London and Imperial College Healthcare NHS Trust

Member of:

British Association of Urological Surgeons

Royal College of Surgeons, England

European Association of Urology

American Association of Urology

Focal Therapy UK (Chair)

Focal Therapy Society (board member)

Clinical interests:

Diagnosis and management of prostate cancer

Diagnosis and management of benign enlarged prostate

Management of lower urinary tract symptoms

Management of prostatitis

Image fusion transperineal prostate biopsy

HIFU and cryotherapy for prostate cancer

Greenlight laser vapourisation for enlarged prostates

Rezum water vapour (steam) therapy for enlarged prostates

Fees, Training & Background:

Professor Hashim Ahmed is an internationally renowned expert in prostate cancer diagnosis, imaging and biopsy as well as minimally invasive therapies for prostate cancer. He is Professor and Chair of Urology at Imperial College London; one of the youngest Chairs of a surgical department in Europe.

He is one the leading experts in diagnosis of prostate cancer, focal therapy and active surveillance of prostate cancer, and treatment of enlarge prostates with Greenlight laser and steam therapy (Rezum). He has taught dozens of surgeons in these techniques in the UK and around the world and given numerous invited international lectures in this area.


He has an extensive research portfolio with approximately £12 million in grant income as a lead applicant and co-applicant to a research programme of approximately £16 million.

He has pioneered research that means men suspected of prostate cancer can avoid invasive biopsies and instead have accurate MRI scans affecting millions of men around the world. He has led international research for less invasive treatments for prostate cancer such as High intensity focused ultrasound (HIFU) and cryotherapy which lead to fewer side-effects and similar cancer control compared to surgery or radiotherapy. This work has led to the award of the British Medical Journal Award for Innovation (2015) and the Health Services Journal Award for Innovation (2016 and 2018). He has also been named as the UK’s top prostate cancer specialist by GHP Private Healthcare Awards (2018 and 2019), Corporate America Today (2019) and Global 100 (2019).

He has published over 250 peer-reviewed papers in areas that have led to key changes in the way we diagnose and treat men with localised prostate cancer. He currently currently holds a prestigious £2.1M Wellcome Trust Senior Clinical Research Fellowship and leads a team of 20 researchers.

Personal website address: